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Abstract. Anaplastic thyroid carcinoma (ATC) is a rare type of thyroid carcinoma with a 
poor prognosis. Thus, suitable preclinical tumor models are required for the development 
of new ATC therapies. In the present study, orthotopic tumor xenograft models were 
established using ATC cell lines and SCID mice, and tumor invasion and the effects of 
anticancer drugs were evaluated using positron emission tomography/computed 
tomography (PET/CT) to repeatedly and non-invasively monitor these models. Three 
ATC cell lines (8305c, 8505c, and ACT-1) were used. Their sensitivities to two anticancer 
drugs (paclitaxel and lenvatinib) were investigated. The 8505c cell line was orthotopically 
implanted into SCID mice, which were then divided into three groups: no chemotherapy, 
paclitaxel (5 mg/kg, administered intraperitoneally, every week), and lenvatinib (5 mg/kg, 
oral route, every day) groups. PET/CT was performed and tumor growth and the effects 
of anticancer drugs based on tumor volume and fludeoxyglucose (FDG) uptake were 
evaluated. 8505c cells exhibited the highest sensitivity to the anticancer drugs. In mice 
implanted with 8505c cells, continuous increases in FDG uptake associated with tumor 
growth were detected on PET/CT in the group that received no chemotherapy. The tumor 
volume and FDG uptake increased by 91.5- and 2.4-fold, respectively, within 2 weeks. 
The increase observed in tumor volume was 26.9- and 12.2-fold in the paclitaxel and 
lenvatinib groups, respectively, within 2 weeks. Furthermore, the increase in FDG uptake 
was 1.8-fold and 1.6-fold in the paclitaxel and lenvatinib groups, respectively, within 2 
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weeks. In our orthotopic SCID mouse model, tumor growth and the effects of anticancer 
drugs were repeatedly and non-invasively monitored using PET/CT. The present method 
is useful for the development of new ATC treatments. 
 
Introduction 
Anaplastic thyroid carcinoma (ATC) is one of the most aggressive human 
malignancies and has a poor prognosis (1-3). The average survival time of patients with 
ATC is approximately 3-4.5 months (1-3), with a 1-year survival rate of only 16-20% (1–
3). Once diagnosed, a large number of ATC tumors cannot be radically resected because 
the disease is too advanced. There are currently no effective chemotherapy regimens for 
ATC, and the majority of patients diagnosed with ATC will succumb to the disease (1-3).  
Doxorubicin has been used to treat ATC, but has only achieved modest effects (4, 5). 
A few effective chemotherapy regimens and drugs have recently been approved as 
treatments for ATC. A phase 2 trial on paclitaxel for ATC patients reported an overall 
response rate (ORR) of 56% (6) Another study demonstrated that the weekly 
administration of paclitaxel for ATC was effective and safe; the ORR was 21% and the 
clinical benefit rate was 73% (7). Lenvatinib is a multikinase inhibitor, and its targets are 
vascular endothelial growth factor receptors 1-3, fibroblast growth factor receptors 1-4, 
plated-derived growth factor receptor-α, and the RET and KIT proto-oncogenes (8). In 
Japan, lenvatinib was approved as a treatment for radically unresectable thyroid cancer, 
including ATC, in 2015 (3). A phase 2, single-arm, open-label study on lenvatinib 
conducted in Japan reported that it resulted in a median progression-free survival period 
of 7.4 months, a median overall survival period of 10.6 months, and an ORR of 24% (3, 
8). 
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ATC is rare; i.e., it only accounts for 1-2% of all thyroid carcinomas (9, 10). The 
aggressive characteristics and rarity of ATC make it difficult to accumulate a sufficient 
number of cases for clinical studies aimed at developing new ATC treatments. The phase 
2 trials on paclitaxel (6) and lenvatinib (8) for ATC patients aforementioned included 
limited numbers of patients (n=17-19). Therefore, the development and establishment of 
suitable preclinical tumor models that may be used to examine the effects of anticancer 
drugs against ATC are required.  
Several animal models of thyroid carcinoma have been created, for example, models 
involving the subcutaneous or orthotopic implantation of cancer cells into 
immunodeficient mice (11-13). In 1889, Paget proposed the ‘seed and soil’ theory, in 
which an organ-specific site provides tumor cells with an appropriate environment for 
local growth and metastasis (14). Orthotopic tumor models may provide a more relevant 
biological setting than subcutaneous xenograft models in terms of the tumor 
microenvironment (12-18). 
However, the main disadvantage of orthotopic tumor models is that difficulties are 
associated with assessing changes in tumor size, except at necropsy. Therefore, it is 
impossible to repeatedly and continuously monitor the same model. It was theorized that 
the use of small-animal positron-emission tomography/computed tomography (PET/CT) 
may overcome these disadvantages. Our group previously performed the non-invasive 
monitoring of the anticancer effects of cisplatin on lung cancer in an orthotopic SCID 
mouse model using 18F-fludeoxyglucose (FDG) PET/CT (19). We also monitored the 
anticancer effects of cisplatin and erlotinib in an orthotopic SCID mouse model of lung 
cancer using both CT and PET/CT (20). 
ATC typically exhibits high glucose metabolism and high FDG uptake in both primary 
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and metastatic lesions (21, 22). The American Thyroid Association recommends the use 
of PET/CT to evaluate distant metastatic disease (21). FDG PET/CT may be used for 
initial staging, early evaluations of treatment responses, and follow-ups (22). In patients 
with ATC, PET/CT is useful for directing clinical management and evaluating the efficacy 
of therapy (21, 22). 
In the present study, orthotopic tumor xenograft models were established using ATC 
cell lines and SCID mice. Tumor growth was also evaluated using PET/CT to repeatedly 
and non-invasively monitor these models. Furthermore, the antitumor effects of paclitaxel 
and lenvatinib against ATC were investigated with PET/CT.  
 
 
Materials and methods 
Cell lines. Three ATC cell lines were used: ACT-1, 8305c, and 8505c. The ACT-1 cell line 
was established at our institute (Tokushima University, Tokushima, Japan). The 8305c 
and 8505c cell lines were provided by the BioResource Center of RIKEN. The ACT-1 
and 8305c cell lines were cultured in Roswell Park Memorial Institute-1640 medium 
(Nissui Pharmaceutical Co., Ltd.), and the 8505c cell line in Minimum Essential Medium 
(Sigma-Aldrich; Merck KGaA) supplemented with 10% fetal bovine serum (Bio-West), 
100 IU/ml of penicillin, and 100 μg/ml of streptomycin (Gibco; Life Technologies; 
Thermo Fisher Scientific, Inc.). Cells were maintained at 37˚C in a humidified incubator 
equilibrated with 5% CO2 and 95% air. Cells were grown in tissue culture flasks, and 
passaged at 5- to 7-day intervals at 80% confluence. Cell morphology and viability were 
monitored by microscopic observations. All cell lines were used after being propagated 
between 10 and 20 times. Information on all cell lines was confirmed and checked using 
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the International Cell Line Authentication Committee (https://iclac.org/) and ExPASy 
Cellosaurus databases (https://web.expasy.org/cellosaurus/).  
 
Drugs. Paclitaxel was purchased from Fujifilm Wako Pure Chemical Corporation and 
lenvatinib from LC Laboratories. 
 
Cell viability after drug exposure. Cells (ACT-1 cells: 4x103; 8305c and 8505c cells: 
2x103) were seeded on 96-well plastic culture plates (100μL/well). ACT-1 cells were 
maintained for 48 h, and 8305c and 8505c cells for 24 h at 37˚C in a humidified incubator 
equilibrated with 5% CO2 and 95% air. They were treated with the intended doses of each 
agent for 48 h. After the incubation period, 3-(4, 5-dimrthylthiazolyl-2)-2, 5-
diphenyltetrazolium bromide (MTT; Nacalai Tesque, Inc.) was added at a final 
concentration of 0.5 mg/ml, and cells were incubated for 4 h under the same conditions 
as aforementioned. Dimethyl sulfoxide (Nacalai Tesque, Inc.) was added, and 
spectrophotometric absorbance was measured at 535 nm with a microplate reader 
(Spectra Max i3; Molecular Devices, LLC) and calculated using the supplied software 
(Soft Max pro, version 7). The control sample was untreated and incubated in an equal 
volume of medium (100μ L/well). Each experiment was performed three times 
independently, and the mean values for the three independent experiments were 
calculated. The concentrations of the agents at which cell growth was inhibited by 50% 
(IC50 values) were assessed using growth-inhibition curves. 
 
Animals. As described in our previous studies involving an orthotopic mouse model of 
lung cancer (19, 20), female nine SCID mice (CB-17/Icr-scidJcl; CLEA Japan, Inc.) (age, 
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6-8 weeks; mean body weight, 20 g) were purchased and maintained at our institution’s 
laboratory for animal experiments (Tokushima University, Tokushima, Japan). Animals 
were housed in Micro-Isolator cages on a layer of wood shavings at 22˚C and 55% 
humidity under a fixed 12-hour light/dark regime. A basic diet (MF; Oriental Yeast Co.) 
and water were available ad libitum. All studies were performed in accordance with the 
guidelines established by the Tokushima University Committee on Animal Care and Use. 
At the end of each in vivo experiment, mice were anesthetized and then euthanized 
humanely by vertebral dislocation (20) or, mice were euthanized when they had lost >20% 
of their baseline body weight or had signs of tracheal compressive symptoms. Death was 
confirmed by observation of respiratory and cardiac arrest. All experimental protocols 
were reviewed and approved by the Animal Research Committee of the University of 
Tokushima, Japan. All sections of this study adhered to the ARRIVE Guidelines for 
reporting animal research (23).  
 
Orthotopic mouse model of anaplastic thyroid cancer. On the day of tumor implantation, 
cells were trypsinized, centrifuged (1,000 rpm, 5 minutes), and resuspended in serum-
free media to produce ACT-1, 8305c, and 8505c cell suspensions with a cell density of 
5x105/μl cells, and 0.4 mg/μl Matrigel (Collaborative Biochemical Products) was then 
added to each cell suspension. Cell suspensions were maintained on ice until the 
implantation procedure. As described in our previous studies involving an orthotopic 
mouse model of lung cancer (19, 20), 9 mice were fully anesthetized via the inhalation of 
1.5% isoflurane, before being injected with tumor cells. A 1-cm transverse incision was 
produced along the middle of the throat. The salivary glands were reflected laterally, the 
trachea was exposed, and the overlaying strap muscles were dissected away from the right 
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thyroid lobe. Once the right thyroid lobe was exposed, the cell suspension (5x105 cells in 
2 μl of medium; Minimum Essential Medium (Sigma-Aldrich; Merck KGaA)) was 
injected into the right thyroid gland using a Hamilton syringe (Thermo Fisher Scientific, 
Inc.) attached to a 30-gauge needle. After the injection of the cell suspension, the salivary 
glands were repositioned and the skin incision was closed with 3-0 silk sutures. After the 
implantation, all mice were weighed and monitored for signs of distress regularly every 
week. 
 
FDG PET/CT-based analysis of tumor volumes and maximum standardized uptake value 
(SUVmax). As described in our previous studies (19, 20), FDG PET/CT scans were 
performed with a Siemens Inveon small-animal PET scanner (Siemens Healthcare). Mice 
that had been orthotopically implanted with 8505c cells were fasted for 12 h, but were 
allowed free access to water. Their body weights were measured, and mice were then 
anesthetized via the inhalation of 1.5-2.0% isoflurane, before 10 MBq/0.1-0.2 ml FDG 
was injected via a tail-vein catheter. The whole body of each mouse was scanned using 
CT [field of view: 32.0x32.0x48.1 mm3]. PET data were acquired for 20 min after a delay 
of 40 min to allow for FDG uptake. PET/CT images were analyzed with PMOD version 
3.7 (PMOD Technologies LLC). In each PET/CT scan, the metabolic tumor volume 
(MTV) was calculated based on the volume of interest (VOI), which was drawn manually 
around the primary tumor on PET/CT images after referring to CT images. Since the 
boundary between the thyroid gland and surrounding structures was unclear on CT alone, 
MTV was used as the tumor volume in the present study. On fused PET images, SUVmax 
was calculated from the maximum voxel value (Bq/ml) in the VOI. Field-of-view of 




Evaluation of tumor growth in mice that had been orthotopically implanted with 8505c 
cells. The period of the tumor growth evaluation study was set from the day of tumor 
implantation to 5 weeks after implantation. In weeks 3 to 5 after the implantation of 
8505c cells, PET/CT measurements on the no treatment group [n=3] were performed 
every 7 days.  
 
Evaluation of the inhibition of tumor growth in mice that had been orthotopically 
implanted with 8505c cells. The period of the tumor growth inhibition study was set 
from the day of tumor implantation to 4 weeks after implantation, since the body weight 
loss of the non-treated mice was 18% and 28% at 4 and 5 weeks after the implantation 
procedure, respectively.  
Two weeks after the implantation of 8505c cells, 6 mice were subjected to PET/CT 
measurements. To select drug doses, we referred to a study by Jing et al (30). The interval 
of paclitaxel administration was modified according to our preliminary examination. Jing 
et al administered paclitaxel twice per week. However, a sufficient antitumor effect was 
confirmed even once a week and marked weight loss was observed when paclitaxel was 
administered twice per week in the present study. Therefore, we adopted a weekly 
administration regimen for the paclitaxel group [n=3, 5 mg/kg, intraperitoneal 
administration, every week], and daily administration regimen for the lenvatinib group 
[n=3, 5 mg/kg, oral administration, every day]. PET/CT measurements were performed 
every 7 days from 2 to 4 weeks after the implantation procedure. 
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Histological examinations. We sacrificed the mice and en bloc resected the bilateral 
thyroid glands, bilateral salivary glands, trachea, bilateral lungs, and mediastinal region. 
The tumors implanted in the thyroid and surrounding organs were cut into 1-2-mm-thick 
pieces in the horizontal direction. These pieces were fixed with 10% formalin at 22˚C for 
one week and embedded in paraffin blocks. Paraffin sections that had been stained with 
hematoxylin and eosin (H&E) were examined under a BX51 polarizing microscope 
(Olympus Corporation, magnification x20, x200). It was not possible to perform a 
pathological examination on the mice subjected to PET/CT because their removal from 
the PET/CT facility was prohibited in order to prevent radiation exposure. 
 
Statistical analysis. Due to animal protection concerns, experiments were conducted with 
the minimum sample size. Statistical methods based on the standard maximum likelihood 
were not applicable. As an alternative, the significance of differences in tumor volume, 




Cell viability after drug exposure. The results of the cell viability assay are presented in 
Fig. 1. The paclitaxel and lenvatinib treatments both dose-dependently inhibited cell 
viability in all cell lines. Among the three cell lines assessed, 8505c cells exhibited the 
highest sensitivity and lowest IC50 (250 nM/l) to paclitaxel (Fig. 1A). All cell lines 
displayed similar levels of sensitivity to lenvatinib (Fig. 1B). 
 
Tumor growth and SUVmax in the 8505c cell-based orthotopic mouse model. In the 
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orthotopic 8505c cell-based model mice, there was no FDG uptake in thyroid tissue 3 
weeks after the implantation procedure on PET/CT (Fig. 2A-a). FDG uptake was 
observed in the right thyroid lobe 4 weeks after the implantation procedure on PET/CT, 
which also revealed lateral deflection of the trachea due to increases in the size of the 
tumors 4 weeks after the implantation procedure (Fig. 2A-b). Mean tumor volumes were 
44.6- and 91.5-fold higher at 4 and 5 weeks after the implantation procedure, respectively, 
than those at 3 weeks after the implantation procedure (Fig. 2B-a). The maximum tumor 
volume and diameter at 5 weeks after the implantation were 1042.9±58.3 mm3 and 
13.3±0.6 mm, respectively (Fig. 2A-c). FDG uptake increased by 2.8-fold from 3 to 4 
weeks after the implantation procedure; however, decreased FDG uptake was observed 
after 5 weeks (Fig. 2B-b). On coronal PET/CT images, FDG uptake inside the tumors had 
decreased at 5 weeks (Fig. 2A-c). The body weights of the mice decreased to a maximum 
28% (Fig. 2B-c). Gross examinations of the tumors revealed that they were approximately 
1.5 cm in diameter (Fig. 3A), and necrotic changes were pathologically observed in the 
central parts of the tumors (Fig. 3B-a) 5 weeks after the implantation procedure. All mice 
were anesthetized and then euthanized humanely by vertebral dislocation at the end of 
the experiment 5 weeks after the implantation procedure, and there was no accidental 
death during the experiment. Orthotopic implantation was also performed with ACT-1 
and 8305c cells as well as 8505c cells. Although tumors were pathologically diagnosed 
in these mouse models, no clear macroscopic tumor formation was observed 6 weeks after 
the implantation of ACT-1 or 8305c cells (data not shown). Since tumors derived from 
ACT-1 or 8305c cells grew markedly slower than those derived from 8505c cells, the 
mouse models involving the implantation of ACT-1 or 8305c cells were not considered 
to be appropriate for assessing the antitumor effects of chemotherapy. Thus, PET/CT-
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based examinations on tumor growth and the antitumor effects of chemotherapy were 
only performed using the 8505c cell-based orthotopic mouse model. 
 
Antitumor effects of paclitaxel and lenvatinib in the 8505c cell-based orthotopic mouse 
model according to FDG PET/CT imaging. We examined the antitumor effects of 
paclitaxel and lenvatinib in mice that had been implanted with 8505c cells using PET/CT. 
No tumors were detected on PET/CT 2 weeks after the implantation procedure in the 
paclitaxel or lenvatinib group (Fig. 4A-a and B-a). FDG uptake was observed at the 
putative tumor sites in both treated groups 3 weeks after the implantation procedure (Fig. 
4A-b and B-b). The size of the tumors on coronal PET/CT images increased from 3 to 4 
weeks after implantation in both treated groups, whereas tumor growth rates were 
markedly slower than that in the no treatment group (Fig. 4A-c and B-c). Throughout the 
treatment period, the increases observed in tumor volume and FDG uptake in the control 
group were suppressed in both treated groups. In the paclitaxel group, the mean tumor 
volumes were 6.6- and 26.9-fold higher at 3 and 4 weeks after the implantation procedure, 
respectively, than that at 2 weeks after the implantation procedure (Fig. 5A). In the 
paclitaxel group, the maximum tumor volume and diameter at 4 weeks after the 
implantation were 595.4±190.0 mm3 and 8.7±1.5 mm, respectively (Fig. 4A-c). In the 
lenvatinib group, the mean tumor volumes were 6.8- and 12.2-fold higher at 3 and 4 
weeks after the implantation procedure, respectively, than that at 2 weeks after the 
implantation procedure (Fig. 5A). In the lenvatinib group, the maximum tumor volume 
and diameter at 4 weeks after the implantation were 216.2±83.9 mm3 and 6.7±0.6 mm, 
respectively (Fig. 4B-c). In the paclitaxel group, FDG uptake increased by 1.5- and 1.8-
fold from 2 to 3 weeks and from 2 to 4 weeks after the implantation procedure, 
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respectively. In the lenvatinib group, FDG uptake increased by 1.4- and 1.6-fold from 2 
to 3 weeks and from 2 to 4 weeks after the implantation procedure, respectively (Fig. 5B). 
A marked antitumor effect was observed from 3 to 4 weeks after the implantation 
procedure in the lenvatinib group (Fig. 5A and B). The maximum body weight loss of the 
mice in the lenvatinib group was 3%, whereas the maximum weight loss in the paclitaxel 
group was 24% at 4 weeks after the implantation procedure (Fig. 5C). All mice in the 




In the present study, the growth of tumors in an orthotopic mouse model that had 
been implanted with 8505c cells was monitored using FDG PET/CT. Th mean tumor 
volumes were 44.6- and 91.5-fold higher 4 and 5 weeks after the implantation procedure, 
respectively, than that 3 weeks after the implantation procedure. The rapid growth of these 
tumors reflects the aggressive characteristics of ATC. Furthermore, the trachea, 
esophagus, and other surrounding tissues were displaced as the tumors grew, which is 
consistent with the clinical course of ATC (24). Conversely, although FDG uptake 
increased from 3 to 4 weeks after the implantation procedure, it decreased from 4 to 5 
weeks. FDG uptake was also only observed at the margins of the tumors, and was not 
detected in the center of the tumors on PET/CT images obtained 5 weeks after the 
implantation procedure. Histological examinations on tumors performed 5 weeks after 
the implantation procedure revealed necrotic changes in the central parts, which were 
surrounded by viable tumor cells. Central tumor necrosis is one of the typical histological 
changes associated with ATC (24, 25). The decrease observed in tumor FDG uptake from 
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4 to 5 weeks after the implantation procedure was considered to have been caused by 
necrotic changes. Therefore, the tumor volume, rather than FDG uptake, needs to be 
measured as an index of tumor growth in orthotopic mouse models involving the 
implantation of 8505c cells. 
We previously reported that FDG PET/CT is useful for monitoring antitumor effects 
in an orthotopic lung cancer model (19, 20). In these studies, the tumor volume was easy 
to calculate based on CT images since the CT values of the tumors and lung fields were 
different (19, 20). Conversely, in the present study, the boundaries between the tumors 
and the surrounding structures of the thyroid gland were unclear on CT images because 
their CT values were similar. Therefore, MTV, which was calculated based on the area of 
FDG uptake, was adopted as the tumor volume in the present study. MTV has been 
reported as a marker that increases the accuracy of prognostication and clinical staging in 
human tumors (26-28). Manohar et al reported that MTV reflected a higher tumor burden 
for patients receiving multikinase inhibitor therapy for metastatic radioiodine-refractory 
differentiated thyroid cancer (28). PET and CT were both considered to be important for 
evaluating tumors in orthotopic xenograft models involving the implantation of ATC cell 
lines into SCID mice.  
The antitumor effects of paclitaxel and lenvatinib in an orthotopic mouse model that 
had been implanted with 8505c cells were examined using PET/CT. In the chemotherapy 
groups, FDG uptake and tumor volume were both lower than those in the no 
chemotherapy group. Therefore, the present study demonstrated that FDG uptake and 
MTV may be used to assess the effects of anticancer drugs in orthotopic mouse models 
involving the implantation of 8505c cells. A previous study reported that lenvatinib 
exerted antitumor and antiangiogenic effects in numerous thyroid cancer xenograft 
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models, including ATC models (29). Furthermore, Jing et al demonstrated the effects of 
lenvatinib and paclitaxel in subcutaneous xenograft models of ATC (30). The effects of 
lenvatinib and paclitaxel in an orthotopic tumor xenograft model of ATC were confirmed 
in the present study. In addition, the effects of the two drugs were objectively 
demonstrated using PET/CT. This is the first study, to the best of our knowledge, to 
demonstrate the antitumor effects of paclitaxel and lenvatinib in an orthotopic tumor 
xenograft model of ATC with PET/CT.  
Orthotopic tumor models provide a suitable preclinical environment for evaluating 
the effects of anticancer drugs (15). The main disadvantage of using orthotopic tumor 
models for this purpose is the difficulty associated with monitoring tumor size. Small-
animal PET/CT was employed to overcome this issue. The use of PET/CT had the 
following advantages. The main advantage was that any changes in tumor size may be 
continuously evaluated in each mouse using PET/CT. By monitoring the changes in tumor 
size that occurred in each individual mouse, we were able to clearly assess tumor growth 
and the therapeutic effects of the anticancer drugs. Conversely, previous studies (16, 17) 
that evaluated the therapeutic effects of anticancer drugs using orthotopic thyroid cancer 
animal models required the sacrifice of more than 6 mice at each time-point to ensure the 
quality of the data obtained; however, the resultant data had no real continuity. Matthew 
et al revealed that anti-BRAFV600E therapy inhibited tumor growth in an orthotopic 
mouse model that had been implanted with 8505c cells (16). Forty-eight mice were 
orthotopically implanted with ATC cells and divided into 8 groups of 6 mice for the 
purpose of establishing the time course of tumor progression and the response to late 
therapeutic interventions with PLX4720, which selectively inhibits BRAFV600E. Each 
week, 6 mice were sacrificed, and tumor growth was evaluated to assess the effectiveness 
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of PLX4720. Cha et al (17) investigated the effects of a perioperative treatment with 
echinomycin, which is a hypoxia-inducible factor-1α inhibitor, using an orthotopic 
surgical mouse model of thyroid cancer. In the latter study, 60 mice were implanted with 
thyroid cancer cell lines. Mice were divided into four groups of 15 mice: a control group, 
surgical group, echinomycin group, and surgical and echinomycin group, and were 
sacrificed to evaluate the effects of each treatment. In the present study, only 9 mice were 
required to evaluate tumor growth and the effects of the two drugs. Therefore, our 
PET/CT-based method appears to be an ideal preclinical experimental system from the 
point of view of animal welfare. 
We were also able to detect tumor formation earlier than previous studies involving 
mouse models in which 8505c cells were orthotopically implanted. Nucera et al 
demonstrated that tumors became palpable 35 days after the implantation of 8505c cells 
(12). However, by using PET/CT, FDG uptake on the right side of the trachea was 
observable 21 days after the implantation procedure in the treatment group. Thus, whether 
each orthotopic mouse model was suitable was confirmed at an early stage.  
Moreover, continuous detailed examinations of tumor growth and its effects on the 
surrounding organs were possible in the same model using PET/CT. Previous studies 
demonstrated that orthotopic models involving the implantation of 8505c cells produced 
large tumors, which resulted in cachexia and death by 35 days after the implantation 
procedure (12, 16). Similar findings to those described in these studies were reproduced 
in our models, and we were able to observe gradual increases in tumor size that displaced 
the trachea and surrounding tissues using PET/CT. However, when the neck tumor 
exceeds a certain size, esophageal compression by the tumor causes insufficient oral 
intake and rapid weight loss. Therefore, conducting experiments within the range of 
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weight loss allowed by the experimental protocols requires careful experimental period 
setting and mouse monitoring. 
Paclitaxel and lenvatinib both improved the prognosis of ATC patients. However, 
the effects of these therapies are limited. The combination of chemotherapy and molecular 
targeted agents was recently evaluated in various cancer fields (31). Combination therapy 
with paclitaxel and lenvatinib may improve the treatment outcomes of ATC, and our 
model has the potential to become an effective tool for the development of this new 
therapy. 
In conclusion, in the present study, the utility of FDG PET-CT for repeated and non-
invasive evaluations of tumor progression and the effects of antitumor drugs (paclitaxel 
and lenvatinib) in orthotopic ATC models were demonstrated. The methods presented in 
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Figure legends 
Figure 1. Effects of chemotherapy drugs (paclitaxel and lenvatinib) on cell viability 
according to the MTT assay. (a) ACT1, (b) 8305c, and (c) 8505c cells were treated with 
(A) paclitaxel or (B) lenvatinib.  
 
Figure 2. CT and PET/CT findings obtained in the no chemotherapy group. (A) Coronal-
view CT and PET/CT images of tumors derived from 8505c cells in the right thyroid lobe. 
The arrows in the upper images indicate the trachea, and the arrow heads in the lower 
images indicate tumors. Scale bars, 5 mm (a) Three weeks after implantation, (b) 4 weeks 
after implantation, and (c) 5 weeks after implantation. (B) Quantitative PET/CT imaging 
data obtained from mice implanted with 8505c cells. (a) Tumor growth rate from 3 to 5 
weeks after implantation. Values on the vertical axis represent the tumor growth rate 
based on the tumor volume at 3 weeks after implantation. (b) The increasing rate of 
SUVmax (FDG uptake) from 3 to 5 weeks after implantation. Values on the vertical axis 
represent the increasing rate of SUVmax based on the SUVmax value at 3 weeks after 
implantation. (c) Body weight from 3 to 5 weeks after implantation. CT, computed 
tomography; PET/CT, positron emission tomography/computed tomography; SUVmax, 
maximum standardized uptake value; FDG, fludeoxyglucose. 
 
Figure 3. Histological findings. (A) Gross examination of a tumor derived from 8505c 
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cells performed 5 weeks after implantation. (B-a) Histological sections of tumors derived 
from 8505c cells. H&E staining (magnification, x20). Th, thyroid lobe; T, tumor; E, 
esophagus; Tr, trachea; arrows, necrotic changes in the central part of the tumor. scale bar, 
1000 μm. (B-b) Magnified image of the white square presented in B-a. H&E staining 
(magnification, x200). Th, thyroid lobe; T, tumor. Scale bar, 100 μm. H&E, hematoxylin 
and eosin. 
 
Figure 4. Coronal CT and PET/CT images of orthotopic mice in treated groups that had 
been implanted with 8505c cells. The arrows in the upper images indicate the trachea, and 
the arrow heads in the lower images indicate the tumors. Scale bar, 5 mm. (A) Paclitaxel 
group and (B) lenvatinib group, (a) three weeks after implantation, (b) 4 weeks after 
implantation, and (c) 5 weeks after implantation. CT, computed tomography; PET/CT, 
positron emission tomography/computed tomography. 
 
Figure 5. Quantitative PET/CT imaging data obtained from mice in treated groups that 
were implanted with 8505c cells. (A) Tumor growth rate from 2 to 4 weeks after 
implantation. Values on the vertical axis represent the tumor growth rate based on the 
tumor volume at 2 weeks after implantation. (B) The increasing rate of SUVmax (FDG 
uptake) from 2 to 4 weeks after implantation. Values on the vertical axis represent the 
increasing rate of SUVmax based on the SUVmax value at 2 weeks after implantation. (C) 
body weight from 2 to 4 weeks after implantation. PET/CT, positron emission 
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